Tasigna (Nilotinib) - Chronic Myeloid Leukemia - CML
''Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor...
It was approved as Tasigna® in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib, also known by its clinical code AMN107, has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to Gleevec®) achieved a normal white blood cell counts after five months of treatment...
'Extract of Wikipedia
VIDEOS
Dr. Donnellan on TFR in Patients With CML Treated With Nilotinib
September 2016, OncLiveTV
What are the efficacy and safety considerations of nilotinib therapy?
April 29, 2016, MediCom Oncology
Nilotinib in the Second-Line Setting
January 11, 2015, OncLiveTV
Dr. Timothy Hughes Compares Imatinib to Nilotinib in Chronic Myeloid Leukemia
January 4, 2013, OncLiveTV
Jayshree Shah on the Safety and Efficacy of Nilotinib for Patients With CML
May 1, 2012, OncLiveTV
Nilotinib Versus Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive CML-CP
January 6, 2012, Oncology.TV
Summary of Cardiac Effects of NILOTINIB and IMATINIB in Patients Enrolled in ENESTND Trial
May 31, 2011, Oncology.TV
Tasigna Global MOA 6 4 08
November 12, 2010, Brendan Carroll
Living with chronic myeloid leukemia (Tasigna® is approved in Canada)
August 2010, Info4YourLife
Tasigna® versus Gleevec®
June 16, 2010, Insidermedecine
Gary Gonzales - Tasigna® patient video
February 24, 2007, TSJAlexander
Dr. Donnellan on TFR in Patients With CML Treated With Nilotinib
September 2016, OncLiveTV
What are the efficacy and safety considerations of nilotinib therapy?
April 29, 2016, MediCom Oncology
Nilotinib in the Second-Line Setting
January 11, 2015, OncLiveTV
Dr. Timothy Hughes Compares Imatinib to Nilotinib in Chronic Myeloid Leukemia
January 4, 2013, OncLiveTV
Jayshree Shah on the Safety and Efficacy of Nilotinib for Patients With CML
May 1, 2012, OncLiveTV
Nilotinib Versus Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive CML-CP
January 6, 2012, Oncology.TV
Summary of Cardiac Effects of NILOTINIB and IMATINIB in Patients Enrolled in ENESTND Trial
May 31, 2011, Oncology.TV
Tasigna Global MOA 6 4 08
November 12, 2010, Brendan Carroll
Living with chronic myeloid leukemia (Tasigna® is approved in Canada)
August 2010, Info4YourLife
Tasigna® versus Gleevec®
June 16, 2010, Insidermedecine
Gary Gonzales - Tasigna® patient video
February 24, 2007, TSJAlexander
ARTICLES
Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib
July 20, 2021, PubMed
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study
July 9, 2021, MDLinx
Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia
March 6, 2021, PubMed
Nilotinib appears safe and affects biomarkers in Alzheimer's disease clinical trial
May 29, 2020, Medical Xpress
Experts Establish Optimal Dosing of Nilotinib for Newly Diagnosed CML
April 14, 2020, Oncology Learning Network
Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): enabling dose reduction and relief of treatment burden
April 3, 2020, PubMed
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia
January 31, 2020, Physicien”s weekly
Nilotinib Therapy Safe, Effective for Certain Patients With CML
January 16, 2020, Oncology Learning Network
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
November 13, 2019, ASH2019
Leukemia drug shows promise for treating a childhood brain cancer - nilotinib
September 2019, Medical Xpress
First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia
Jun 25, 2019, Synapse.
Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
June 14, 2019, PubMed
Treatment-Free Remission After Nilotinib May Be Durable in Chronic Myeloid Leukemia
June 3, 2019, Hematology Advisor
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL)
May 26, 2019, Journal of Clinical Oncology
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
March 2019, Blood Advances
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
September 2018, PubMed
Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML
June 3, 2018, Cancer Therapy Advisor
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
June 2, 2018, PR Newswire
Tasigna – Atherosclerosis WARNING
May 11, 2018, US Recall News
Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML
March 5, 2018, Oncology Nurse Advisor
Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia
January 19, 2018, National Cancer Institute
MolecularMD Gets FDA Authorization for Companion Dx to Novartis CML Drug
December 27, 2017, GenomeWeb
FDA Updates Labeling for Nilotinib: Treatment Can Be Stopped
December 22, 2017, Medscape
Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults
December 11, 2017, Oncology Nurses Advisor
Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib
December 2017, ASH2017
Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial
December 2017, ASH2017
Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy
December 2017, ASH2017
Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with CML: A Real Life Observational Study (NILO-RED)
December 2017, ASH2017
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib
January 8, 2017, PubMed
Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials
December 2016, ASH2016
Two-Year Consolidation By Nilotinib Is Associated with Successful Treatment Free Remission in Chronic Myeloid Leukemia with MR4.5: Subgroup Analysis from STAT2 Trial in Japan
December 2016, ASH2016
Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
July 28, 2016, American Journal of Hematology
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
December 7, 2015, Blood Journal
Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase
December 7, 2015, Blood Journal
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
December 7, 2015, Blood Journal
KIR2DL5B Associated With Poor Response in CML Treated With Sequential Imatinib, Nilotinib
October 26, 2015, Cancer Therapy Advisor
Long-Term Data Highlights Nilotinib Efficacy, Cardiovascular Effects
July 14, 2015, Cancer Network
Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia
June 29, 2015, PubMed
Novel Imatinib/Nilotinib Strategy Could Optimize CML Treatment
March 17, 2015, Cancer Network
First- and Second-Line Nilotinib in CML
March 10, 2015, OncLive
Nilotinib plus chemotherapy pays off for older patients with Ph+ALL
December 9, 2014, The Oncology Report
Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia
July 2014, Haematologica
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo
June 16, 2014, Journal Blood
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM)
June 2,2014, 2014 ASCO Annual Meeting
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
February 27, 2014, Blood
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia
October 2013, Heamatologica
Nilotinib Associated With Increased Peripheral Artery Disease Rate in CML WARNING
May 13, 2013, Cancer Network
TASIGNA® (nilotinib) - Possible Risk of Developing Atherosclerosis-Related Conditions - For the Public
April 12, 2013, Health Canada
Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib
September 2012, Science Direct
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
July 5, 2012, PubMed
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
May 24, 2012, Unbound Medline
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete genetic response during first-line nilotinib therapy.
April 19, 2012, PubMed
Clinical cardiac safety profile of nilotinib.
January 22, 2012, PubMed
The Apothecary Shops Incorporates Innovative Technology Into Patient Medication Reminders
December 19, 2011, PRNewswire
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
November 11, 2011, PubMed
Nilotinib Beats Imatinib at 24 Months in Treatment of CML
June 20, 2011, Medscape Today
Nilotinib Superior to Imatinib, Fewer Mutations in Treatment of CML-CP
June 6, 2011, Monthly Prescribing Reference
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
November 13, 2010, JASN
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
June 5, 2010, The New England Journal of Medecine
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
December 9, 2009, Insciences organisation
Nilotinib for the frontline treatment of Ph+ chronic leukemia
December 3, 2009, Blood, Vol.114, No.24, pp.493304938
Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants
November 30, 2009, PubMed
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib
November 18, 2009, PubMed
Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study
November 15, 2009, PubMed
Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
November 15, 2007, Journal Blood
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
June 2007, NCBI
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
September 15, 2005, PubMed
New era drug gives hope to Gleevec® resistant leukaemia sufferers
April 19, 2005, News Medical
Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib
July 20, 2021, PubMed
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study
July 9, 2021, MDLinx
Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia
March 6, 2021, PubMed
Nilotinib appears safe and affects biomarkers in Alzheimer's disease clinical trial
May 29, 2020, Medical Xpress
Experts Establish Optimal Dosing of Nilotinib for Newly Diagnosed CML
April 14, 2020, Oncology Learning Network
Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): enabling dose reduction and relief of treatment burden
April 3, 2020, PubMed
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia
January 31, 2020, Physicien”s weekly
Nilotinib Therapy Safe, Effective for Certain Patients With CML
January 16, 2020, Oncology Learning Network
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
November 13, 2019, ASH2019
Leukemia drug shows promise for treating a childhood brain cancer - nilotinib
September 2019, Medical Xpress
First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia
Jun 25, 2019, Synapse.
Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
June 14, 2019, PubMed
Treatment-Free Remission After Nilotinib May Be Durable in Chronic Myeloid Leukemia
June 3, 2019, Hematology Advisor
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL)
May 26, 2019, Journal of Clinical Oncology
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
March 2019, Blood Advances
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
September 2018, PubMed
Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML
June 3, 2018, Cancer Therapy Advisor
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
June 2, 2018, PR Newswire
Tasigna – Atherosclerosis WARNING
May 11, 2018, US Recall News
Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML
March 5, 2018, Oncology Nurse Advisor
Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia
January 19, 2018, National Cancer Institute
MolecularMD Gets FDA Authorization for Companion Dx to Novartis CML Drug
December 27, 2017, GenomeWeb
FDA Updates Labeling for Nilotinib: Treatment Can Be Stopped
December 22, 2017, Medscape
Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults
December 11, 2017, Oncology Nurses Advisor
Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib
December 2017, ASH2017
Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial
December 2017, ASH2017
Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy
December 2017, ASH2017
Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with CML: A Real Life Observational Study (NILO-RED)
December 2017, ASH2017
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib
January 8, 2017, PubMed
Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials
December 2016, ASH2016
Two-Year Consolidation By Nilotinib Is Associated with Successful Treatment Free Remission in Chronic Myeloid Leukemia with MR4.5: Subgroup Analysis from STAT2 Trial in Japan
December 2016, ASH2016
Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
July 28, 2016, American Journal of Hematology
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
December 7, 2015, Blood Journal
Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase
December 7, 2015, Blood Journal
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
December 7, 2015, Blood Journal
KIR2DL5B Associated With Poor Response in CML Treated With Sequential Imatinib, Nilotinib
October 26, 2015, Cancer Therapy Advisor
Long-Term Data Highlights Nilotinib Efficacy, Cardiovascular Effects
July 14, 2015, Cancer Network
Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia
June 29, 2015, PubMed
Novel Imatinib/Nilotinib Strategy Could Optimize CML Treatment
March 17, 2015, Cancer Network
First- and Second-Line Nilotinib in CML
March 10, 2015, OncLive
Nilotinib plus chemotherapy pays off for older patients with Ph+ALL
December 9, 2014, The Oncology Report
Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia
July 2014, Haematologica
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo
June 16, 2014, Journal Blood
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM)
June 2,2014, 2014 ASCO Annual Meeting
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
February 27, 2014, Blood
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia
October 2013, Heamatologica
Nilotinib Associated With Increased Peripheral Artery Disease Rate in CML WARNING
May 13, 2013, Cancer Network
TASIGNA® (nilotinib) - Possible Risk of Developing Atherosclerosis-Related Conditions - For the Public
April 12, 2013, Health Canada
Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib
September 2012, Science Direct
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
July 5, 2012, PubMed
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
May 24, 2012, Unbound Medline
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete genetic response during first-line nilotinib therapy.
April 19, 2012, PubMed
Clinical cardiac safety profile of nilotinib.
January 22, 2012, PubMed
The Apothecary Shops Incorporates Innovative Technology Into Patient Medication Reminders
December 19, 2011, PRNewswire
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
November 11, 2011, PubMed
Nilotinib Beats Imatinib at 24 Months in Treatment of CML
June 20, 2011, Medscape Today
Nilotinib Superior to Imatinib, Fewer Mutations in Treatment of CML-CP
June 6, 2011, Monthly Prescribing Reference
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
November 13, 2010, JASN
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
June 5, 2010, The New England Journal of Medecine
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
December 9, 2009, Insciences organisation
Nilotinib for the frontline treatment of Ph+ chronic leukemia
December 3, 2009, Blood, Vol.114, No.24, pp.493304938
Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants
November 30, 2009, PubMed
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib
November 18, 2009, PubMed
Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study
November 15, 2009, PubMed
Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
November 15, 2007, Journal Blood
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
June 2007, NCBI
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
September 15, 2005, PubMed
New era drug gives hope to Gleevec® resistant leukaemia sufferers
April 19, 2005, News Medical